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ABSTRACT
Introduction: Current guidelines recommend
insulin for patients with type 2 diabetes
(T2D) and severe hyperglycemia, but this
recommendation lacks sufficient evidence and
poses practical challenges. It is unclear whether
non-insulin treatments are effective in this
setting. The objective of this study was to
describe treatment strategies of T2D patients
with severe hyperglycemia and identify which
initial treatments, interventions, or patient
characteristics correlated with successful
glucose lowering.
Methods: This was a retrospective cohort study
of 114 patients with T2D and a glycosylated
hemoglobin (A1C) C12%. Changes in A1C
were compared between patients started on
non-insulin medications versus insulin-based
regimens. Regression analysis was performed to
assess predictors of success in achieving A1C
B9% within 1 year. The main outcomes measures
were change in A1C from baseline and predictors of
success in achieving A1C B9% within 1 year.
Results: At baseline, 43 patients (37.7%) started
one or more non-insulin medications; 71 (62.3%)
started insulin. Fifty-eight patients (50.8%)
achieved an A1C B9%. Predictors of success
were newly diagnosed T2D, certified diabetes
educator (CDE) visits, and less time to follow-up
A1C; insulin therapy was not. Change in A1C
was significantly better in the non-insulin cohort
compared to the insulin cohort (-4.5% vs.
-2.8%, p = 0.001). Newly diagnosed patients
were less likely to start insulin therapy (20.8%
vs. 73.3%, p\0.001), less likely to use insulin at
any point (29.2% vs 81.1%, p\0.001), and more
likely to achieve an A1C B9% compared to
patients with established T2D (87.5% vs 41.1%,
p\0.001).
Conclusion: Insulin therapy was used in
roughly two-thirds of patients with severe
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hyperglycemia, but did not result in better
glycemic control compared to non-insulin
regimens. Rapid follow-up, more CDE visits,
and a new diabetes diagnosis were predictors of
successful glucose lowering. Patients with T2D
and severe hyperglycemia, particularly those
newly diagnosed, may be managed with non-
insulin therapy.
Keywords: Diabetes mellitus type 2;
Hyperglycemia; Insulin; Primary care
INTRODUCTION
Diabetes affects 25.8 million people (8.3%) in
the USA. There were 1.9 million new cases
diagnosed in 2010 alone [1]. While the
diagnostic threshold for diabetes is an A1C
C6.5%, patients can present with severe
hyperglycemia with A1C values reaching higher
than 14%. Severe hyperglycemia may warrant
specific and immediate treatment considerations
to prevent acute complications, alleviate
symptoms, and preserve beta cell function [2, 3].
However, literature regarding the effectiveness
of different treatment approaches to manage
patients with non-emergent, severe
hyperglycemia is limited.
The American Diabetes Association’s (ADA)
position statement on a patient-centered
approach to the management of hyperglycemia
in type 2 diabetes recommends that ‘‘if a patient
presents with significant hyperglycemic
symptoms and/or has dramatically elevated
plasma glucose concentrations ([300–350 mg/
dL), or an A1C C10–12%, insulin therapy should
be strongly considered from the outset’’ [3]. After
symptoms are relieved and glucose levels are
decreased, oral agents can be added and it may be
possible to withdraw insulin, if preferred. This
recommendation makes no distinction between
newly diagnosed or drug-naı¨ve patients and
treated or established patients, and does not
provide references or level of evidence.
The American Association of Clinical
Endocrinologists (AACE) algorithm for
glycemic control recommends insulin therapy
± other agents for patients who present with an
A1C [9% [4]. The recommendations state that
‘‘for drug naı¨ve patients with A1C levels[9%, it
is unlikely that 1, 2, or even 3 agents (other than
insulin) will achieve the A1C goal’’. The
algorithm does, however, suggest that
treatment with combination non-insulin agents
in drug-naı¨ve patients who do not have
symptoms may be sufficient. References or
levels of evidence are not provided.
Although consensus statements suggest
initiating insulin therapy, this is challenging
in real-world practice. Successful insulin
initiation requires time, resources, knowledge,
proper dose titration, significant patient
education and training, self-monitoring of
blood glucose, and frequent follow-up [3]. In
the primary care setting, many barriers exist,
including time restraints, patient resistance,
and lack of available resources and trained
staff that make it difficult to initiate insulin
therapy in a safe and effective manner.
The lack of sufficient evidence and the
practical challenges posed by initiating
insulin therapy support the need for further
evaluation of treatment approaches to severe
hyperglycemia in T2D patients. Therefore, the
purpose of this study was to (1) describe the
patient characteristics and initial management
strategies of patients with T2D who presented
with A1C values C12%, (2) compare the changes
in A1C from baseline to 12 months between
patients prescribed insulin-based treatment
versus patients prescribed non-insulin-based
treatment, and (3) identify which initial
treatments, interventions, or patient
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This study was a retrospective observational
cohort study of patients with a new or
established diagnosis of type 2 diabetes
presenting within the University of Colorado
Hospital (UCH) ambulatory clinic system with
non-emergent, severe hyperglycemia, defined as
a measured hemoglobin A1C of C12%. Clinics
were primarily internal medicine and family
medicine practices. The study was approved by
the Colorado Multiple Institutional Review
Board and the Hospital Research Review Board
for the UCH. Patients with an A1C value C12%
during the time period of January 1, 2006 to
March 31, 2011 were identified. Electronic
medical records (EMR) for each patient were
reviewed. Data were reviewed from the date of
initial presentation of patients with A1C C12%
(defined as baseline) and followed through
1 year. Study data were collected and managed
using a secure, electronic data capture tool [5].
Data collection included patient demographics
(age, sex, weight, race/ethnicity, duration of
diabetes, insurance status), initial treatment for
diabetes within 1 month of initial presentation,
diabetes medications subsequently used after
1 month, A1C values from date of initial
presentation through 1 year, the number of
visits with an endocrine provider or a certified
diabetes educator, the number of total clinic
visits with diabetes listed in the medical
problem list, the number of hospitalizations or
emergency department visits with diabetes
listed in the medical problem list, and time to
first follow-up visit after initial A1C level C12%.
The analysis in this article is based on
previously conducted studies and does not
involve any new studies of human or animal
subjects performed by any of the authors.
Patient Population
Patients were included in the study if they were
at least 18 years of age, had an A1C C12%
drawn from a UCH ambulatory clinic, and had a
new or established diagnosis of type 2 diabetes.
Patients were excluded if they were less than
18 years of age, had type 1 diabetes, had no
follow-up A1C reading within 12 months of
initial presentation, were pregnant, were taking
corticosteroids, or were diagnosed with
stress-induced hyperglycemia, hyperglycemic
hyperosmolar state, or diabetic ketoacidosis.
Study Cohorts
Clinical Response Cohorts
Patients were categorized into two cohorts
based on a clinically meaningful improvement
in glycemic control: (1) responders, defined as
those patients who achieved an A1C B9%
within 1 year of baseline, and (2) non-
responders, those who did not achieve an A1C
B9% within 1 year of baseline. A regression
analysis was performed to identify what factors
served as predictors of success in achieving an
A1C B9%.
Initial Treatment Cohorts
Patients were stratified into two cohorts based
on initial treatment medication prescribed
within 1 month of baseline: (1) one or more
non-insulin medications and (2) one or more
insulin medications with or without non-
insulin medications. Non-insulin medications
included metformin, glyburide, glipizide,
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glimepiride, sitagliptin, saxagliptin, linagliptin,
pioglitazone, rosiglitazone, repaglinide,
nateglinide, acarbose, miglitol, pramlintide,
liraglutide, or exenatide. Changes in A1C from
baseline to 12 months were compared between
the cohorts using a last observation carried
forward method.
Outcomes
The outcomes of the study were: (1) descriptive
results of patient characteristics and initial
management strategies of patients with T2D
who presented with A1C values C12%, (2)
predictors of success that correlated with
clinically meaningful glycemic response,
defined as achieving an A1C B9% within
1 year, and (3) change in A1C from baseline to
12 months between patients prescribed insulin-
based treatment versus patients prescribed non-
insulin-based treatment.
Statistical Analysis
Demographic measures were summarized by
their mean (SD) or n (%) for categorical
measures. Comparisons of mean and
categorical frequencies across the clinical
response cohorts were tested using the t test or
the Chi-squared test. The Welch corrected t test
was used for continuous data that were not
normally distributed. Comparison of baseline
A1C to the end-point A1C was conducted using
paired t test. Comparing changes in A1C
between the cohorts was conducted using two
sample t tests and the analysis of covariance
(ANCOVA) model using baseline A1C and
diagnosis status as covariates. These analyses
were conducted using last observation carried
forward. Logistic regression analysis was used to
determine predictors of clinical response. Days
to first follow-up, days to first A1C follow-up,
number of endocrine visits, number of CDE
appointments, number of other visits, insulin
medication prescribed at any point during the
year, and health insurance status (public or
none vs. private) were considered as
explanatory variables. The a priori level of
significance was defined as p\0.05. All
analyses were performed using SAS 9.3
software (SAS Institute, Inc., Cary, NC, USA).
RESULTS
A total of 242 patients were identified who
presented to a UCH outpatient clinic with an
A1C C12% during the study period. After
excluding patients primarily due to type 1
diabetes diagnosis or lack of follow-up A1C, a
sample of 114 patients was included in the
final analysis. The average age of the patient
population was 53 years, 64 (47.4%) were male,
and 84 (73.7%) were non-Hispanic. The average
baseline A1C was 13.1%, average weight was
91.9 kg, and average duration of diabetes was
10 years. Twenty-four patients (21.1%) did not
have a previous diagnosis of T2D at the time of
presenting with an A1C C12%. Initial treatment
strategies are shown in Table 1. Within 1 month
of baseline, 43 patients (37.7%) started one or
more non-insulin medications rather than
initiating insulin. Of those, 20 started a single
non-insulin medication, the majority of which
was metformin. Seventy-one patients (62.3%)
initially started an insulin-based regimen.
Of the 114 patients, 58 (50.8%) were
classified as responders (i.e., achieved an A1C
B9% within 1 year) and 56 (49.1%) were
classified as non-responders. Comparisons
between responders and non-responders are in
Table 2. Responders were slightly older (54.7 vs
50.7 years, p = 0.032) and more likely to be
newly diagnosed with T2D compared to
non-responders (36.2% vs 5.4%, p\0.001).
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Responders were less likely to initiate therapy
with insulin (51.7% vs 73.2%, p = 0.019) and
more likely to be initiated on a single
non-insulin medication (25.9% vs 8.9%,
p = 0.014). Responders were found to have
significantly more visits with a CDE (1.2 ± 1.5
vs 0.4 ± 1, p = 0.002) and more likely to have
fewer days to the first follow-up A1C (120 ±
72.6 vs. 154.7 ± 97.5, p = 0.033). Significantly
more patients received insulin at some point in
the year in the non-responder group compared
to the responder group (82.1% vs 58.6%,
p = 0.006).
Results of the regression analysis to
determine predictors of response are in
Table 3. A new diagnosis of diabetes, less days
to first A1C follow-up, and more CDE visits were
found to be predictors of response, while insulin
treatment and number of endocrine clinic visits
were not.
Changes in A1C from baseline are in Table 4.
The average A1C reduction in the total patient
population was 3.5%. The non-insulin-treated
cohort had a significantly greater reduction in
A1C compared to the insulin-treated cohort
(-4.5% vs -2.8%, p = 0.0011). Additionally, a
significantly greater percentage of patients in
the non-insulin cohort achieved an A1C B9%
compared to the insulin-treated cohort (65.1%
vs. 42.3%, p = 0.0179). Within diagnosis status
subgroups (newly diagnosed vs. established
diabetes), the changes in A1C from baseline
were not significantly different between insulin-
treated and non-insulin-treated cohorts
(Table 4). In addition, the ANCOVA model
showed no evidence that A1C decreases
differed significantly between insulin and non-
insulin use after controlling for baseline A1C
and diagnosis status.
A new diagnosis of T2D at the time of
presenting with an A1C C12% was found to be
a confounding variable in the regression
analysis. Therefore, additional post hoc
analyses were performed to evaluate results
between newly diagnosed and previously
diagnosed patients. There were significantly
greater reductions in A1C in newly diagnosed
patients compared to patients with established
diabetes (-6.3% vs. -2.7%, p = 0.001, Table 5),
with A1C differences emerging within
3–5 months from baseline (Fig. 1). Twenty-one
out of 24 newly diagnosed patients (87.5%)
were classified as responders, achieving an A1C
B9%, which was significantly higher than the
41.1% of patients with established diabetes
(p\0.001). In addition, 17 (70.9%) of the
newly diagnosed population achieved the
ADA-recommended goal A1C of B7% as
opposed to 12 (13.3%) of previously diagnosed
patients. This occurred despite the fact that
newly diagnosed patients were less likely to be
initially treated with insulin (20.8% vs. 73.3%,
p\0.001) or receive insulin at any point
throughout the year (29.2% vs. 81.1%,
p\0.001). Of note, 16 of the 24 patients
(67%) started a single non-insulin medication;
14 of those achieved an A1C B9% and 10 of
those achieved the ADA-recommended A1C of
B7% within a year. Details regarding the other
initial treatment regimens of newly diagnosed
patients are shown in Table 6.
Table 1 Initial management strategies
Initial management strategy
within 1 month of baseline
Number of
patients (%)
One or more non-insulin medications 43 (37.7)
Single non-insulin medication 20 (17.5)
Two or more non-insulin medications 23 (20.2)
Insulin-based regimen 71 (62.3)
Insulin plus non-insulin 43 (37.7)
Basal insulin alone 10 (8.8)
Basal plus bolus insulin 18 (15.8)
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DISCUSSION
This study revealed that, although clinical
guidelines recommend insulin therapy for
patients with T2D presenting with severe
hyperglycemia, only about two-thirds of
patients in this study were initiated on an
insulin-based regimen. Over one-third of
patients were treated with non-insulin
medications with 17.5% starting on a single
non-insulin medication. Regardless of
adherence to guideline recommendations,
50.8% of the total population (n = 58)
achieved an A1C B9% by the end of the year.
No correlation was found between any specific
medication regimen and meaningful glucose
response.
The current study provides useful insight
into real-world use of insulin therapy in this
patient population. Overall, insulin use in the
responder group was lower than anticipated
with only about half initiating insulin-based






Mean age, years (range) 54.7 (22–74) 50.7 (28–72) 0.032
Sex, No. (% men) 27 (46.6) 27 (48.2) 0.86
Non-hispanic, no. (%) 43 (74.1) 41 (73.2) 0.91
Mean weight at baseline, kg (SD) 91.9 (32.6) 93.2 (29.0) 0.82
Insurance (non-government), no. (%) 28 (48.3) 27 (48.2) 0.99
Mean baseline A1C, % (SD) 13.2 (0.8) 13.0 (0.9) 0.28
Mean duration of diabetes, years (SD) 10.0 (7.4) 10.6 (7.0) 0.72
New T2D diagnosis at baseline, no. (%) 21 (36.2) 3 (5.4) \0.001
Initial treatment with insulin-based regimen, no. (%) 30 (51.7) 41 (73.2) 0.019
Insulin prescribed at any point in year, no. (%) 34 (58.6) 46 (82.1) 0.006
First follow-up visit, days (SD) 42.7 (57.8) 65.0 (84.9) 0.11
First follow-up A1C, days (SD) 120.0 (72.6) 154.7 (97.5) 0.033
CDE visits, no. (SD) 1.2 (1.5) 0.4 (1.0) 0.002
Endocrine visits, no. (SD) 1.2 (1.8) 1.1 (1.6) 0.67
Other appointments, no. (SD) 4.2 (3.0) 3.8 (3.1) 0.38
A1C glycosylated hemoglobin, CDE certiﬁed diabetes educator, T2D type 2 diabetes
Table 3 Logistic regression modeling the odds of success






Newly diagnosed 11.2 2.3–55.6 0.003
Days to ﬁrst follow-up
A1C
1.0 0.9–1.0 0.042
CDE visits 1.9 1.2–2.9 0.007
Endocrine visits 0.8 0.6–1.1 0.21
Insulin therapy 0.1 0.0–0.4 0.25
A1C glycosylated hemoglobin, CDE certiﬁed diabetes
educator
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therapy. In addition, patients treated with
insulin were actually less likely to achieve an
A1C B9% and had less reduction in A1C from
baseline compared to non-insulin-treated
patients. Possible explanations for this lack of
effect with insulin include inadequate dose
titration or sub-optimal adherence. Patients
prescribed insulin could be more challenging
to treat or more likely to have experienced past
treatment failures.
This analysis did determine that more visits
with a CDE was a predictor of successful






Mean baseline A1C, % (SD) 13.4 (1.0) 13 (0.7) 0.055
Change in A1C from baselinea, % (SD) -6.3 (1.5) -2.7 (2.5) 0.001
Respondersb, no. (%) 21 (87.5) 37 (41.1) \0.001
Initial treatment with insulin, no. (%) 5 (20.8) 66 (73.3) \0.001
Insulin at some point, no. (%) 7 (29.2) 73 (81.1) \0.001
Initial treatment with one non-insulin medication, no. (%) 16 (66.7) 4 (4.4%) \0.001
CDE visits, no. (SD) 1.2 (1.5) 0.7 (1.3) 0.13
First follow-up A1C, no. (SD) 128.8 (99.1) 139.2 (84.1) 0.64
A1C glycosylated hemoglobin, CDE certiﬁed diabetes educator
a Using last observation carried forward
b Achieved A1C B9% within 1 year






from baseline, % (SD)
p value
All patients 114 13.1 (0.8) 9.6 (2.5) -3.5 (2.7) \0.001
Treatment cohort 114 0.001
Non-insulin treated 43 13.2 (1.0) 8.6 (2.3) -4.5 (2.6)
Insulin treated 71 13 (0.7) 10.2 (2.5) -2.8 (2.7)
Newly diagnosed 24 0.56
Non-insulin treated 19 13.5 (1.1) 7.1 (1.2) -6.4 (1.6)
Insulin treated 5 13.3 (0.6) 7.4 (1.3) -5.9 (1.5)
Established diagnosis 90 0.40
Non-insulin treated 24 12.9 (0.8) 9.9 (2.2) -3.1 (2.3)
Insulin treated 66 13 (0.7) 10.4 (2.4) -2.6 (2.6)
A1C glycosylated hemoglobin
a A1C at month 12 or last observation carried forward
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glycemic response. This finding is consistent
with current clinical evidence and ADA and
AACE consensus statements that emphasize
diabetes self-management education as a vital
component of diabetes care [6–8]. Responders
also had fewer days to their first follow-up A1C
compared to non-responders (120.0 vs.
154.7 days). While this difference suggests that
close follow-up is an important component of
glycemic control, our results show that even in
this high-risk population, follow-up A1C
monitoring is routinely delayed past the
recommended 3 months.
A new diagnosis of diabetes was a
confounding variable in our analysis. Patients
who were newly diagnosed were much more
likely to experience success than patients with
an established diagnosis of T2D. Many newly
diagnosed patients experienced success despite
the fact that they were more likely to start a
single non-insulin medication and less likely to
use insulin at any point. This finding suggests
that the time of diagnosis status (i.e., new
versus established diagnosis) may be a key
consideration when determining treatment
approaches in addition to the severity of
hyperglycemia. Prospective studies evaluating
the safety and efficacy of non-insulin treatment
options in newly diagnosed patients with severe
hyperglycemia are warranted.
Several limitations to this study exist. First,
this was a retrospective study performed at a
single institutional system with a relatively
small sample size and may not be able to be
extrapolated to all patients with T2D and severe
hyperglycemia. If more patients had been
included, additional predictors of response
might have been identified through this
analysis. Second, selection bias is also a
potential limitation of this study. The initial
treatment regimen prescribed to a patient could
have been impacted by patient factors not
evaluated in the study. For example, patients
that were prescribed insulin therapy could have
been more difficult to treat or could have
Fig. 1 Mean A1C levels over 12 months. Deﬁnitions:
established diagnosis (squares), new diagnosis (diamonds).
*p value\0.001. A1C glycosylated hemoglobin
Table 6 A1C achievement in newly diagnosed patients based on initial treatment
Initial diabetes treatment Achievement of
A1C £9%, no. (%)
Achievement of
A1C £7%, no. (%)
Total (n = 24) 21 (87.5) 17 (70.9)
One non-insulin medication (n = 16) 14 (58.3) 10 (41.7)
2 or more non-insulin medications (n = 3) 3 (12.5) 3 (12.5)
Insulin only regimen (n = 2) 1 (4.2) 1 (4.2)
Insulin ? non-insulin regimen (n = 3) 3 (12.5) 3 (12.5)
A1C glycosylated hemoglobin
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already failed non-insulin medications, making
it more difficult to attain glycemic control. In
addition, medication dose adjustments and
adherence were not evaluated. This is an
important limitation considering that other
studies have identified that the most
important factor in glycemic success with
insulin is intensifying therapy
[9, 10]. It is highly likely that, in this real-
world clinical setting, several patients in the
insulin-treated cohort did not have their insulin
regimen intensified sufficiently to achieve
successful glycemic control. Third, we defined
glycemic response as achieving an A1C B9%
within the first year. This A1C value does not
meet the general target A1C recommended by
the ADA, but was determined by the authors, a
priori, to constitute a clinically meaningful A1C
reduction in this severe hyperglycemia
population. Fourth, subjects were regarded as
an ‘‘intent to treat’’ population. If a patient
started therapy with a non-insulin medication
within 1 month of baseline, they remained in
the non-insulin cohort throughout analysis,
regardless of whether they later received
insulin medications.
CONCLUSION
The results from this retrospective study show
that a new diagnosis of diabetes, more visits
with a certified diabetes educator, and fewer
days to first follow-up A1C were predictors of
success in achieving an A1C B9%, whereas
insulin therapy was not. Furthermore, it was
observed that insulin therapy did not lead to
better A1C reductions or higher odds of
achieving an A1C B9% compared to non-
insulin regimens, regardless if the patient was
newly diagnosed or had an established
diagnosis. A new diagnosis of diabetes was a
confounding variable. Meaningful glucose
reductions were much more likely in newly
diagnosed patients than those with established
diabetes regardless of the treatment approach.
Despite limitations, this study suggests that
patients with T2D and severe hyperglycemia,
particularly those newly diagnosed, may be able
to be managed with non-insulin therapy.
Further randomized prospective studies are
warranted to confirm this.
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